Please ensure Javascript is enabled for purposes of website accessibility

Why Trevena Stock Surged Today

By Joe Tenebruso – Aug 10, 2020 at 4:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's innovative painkiller is the first new drug in its class in decades.

What happened

Shares of Trevena (TRVN -3.38%) soared 31.5% on Monday after the biopharmaceutical company announced regulatory approval of its new pain-management treatment. 

So what

Trevena said the U.S. Food and Drug Administration (FDA) approved its new opioid agonist, called Olinvyk, for the management of acute pain in adults severe enough to require an intravenous opioid pain reliever -- and for whom other treatments are insufficient.

A stethoscope surrounding the words pain management written on a piece of paper.

Trevena's stock soared on excitement for its new pain-relieving drug. Image source: Getty Images.

In trials with a total of more than 1,500 participants, Olinvyk demonstrated rapid pain-relieving effects in as little as 2-5 minutes. Olinvyk was also shown to be safe and well-tolerated in a variety of people, including those with medical complications.

"Complex patients present unique challenges in the management of their postoperative acute pain, due to the presence of medical comorbidities that can complicate dosing," Stanford University professor Gregory Hammer said in a press release. "Olinvyk represents a new alternative for clinicians, due to its rapid onset of action, effective pain relief, and unique profile."

Now what 

Trevena intends to make Olinvyk commercially available in the fourth quarter after the U.S. Drug Enforcement Administration (DEA) issues its controlled substance schedule in approximately 90 days. Pain management is a massive market, with roughly 45 million hospital patients in the U.S. alone receiving IV opioid treatments each year.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trevena, Inc. Stock Quote
Trevena, Inc.
TRVN
$0.15 (-3.38%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.